Fig 1.
PRISMA flow diagram.
Fig 2.
Network diagram for the base-case analysis.
Table 1.
Characteristics of trials included in the NMA.
Fig 3.
PASI response at end of induction—placebo-adjusted.
Table 2.
Treatment effects at each level of PASI response for all interventions versus placebo at the end of induction.
Number needed to treat included for PASI 100 –placebo-adjusted base-case.
Table 3.
Risk ratios for each pairwise comparison of IL-17As or IL-17RA vs IL-23 or IL-12/23 therapies at PASI 75, 90 and 100 from placebo-adjusted base-case analysis: median risk ratio (95% credible interval).